Nothing Special   »   [go: up one dir, main page]

Dubber et al., 1968 - Google Patents

In vitro and in vivo studies with Trasylol, an anticoagulant and a fibrinolytic inhibitor

Dubber et al., 1968

Document ID
7410794864431172823
Author
Dubber A
McNicol G
Uttley D
Douglas A
Publication year
Publication venue
British Journal of Haematology

External Links

Snippet

Trasylol is a competitive inhibitor of plasminogen activation by streptokinase and urokinase. The proteolytic activity of plasmin and trypsin is inhibited non‐competitively and the esterolytic activity of urokinase is inhibited in a mixed competitive and non‐competitive …
Continue reading at onlinelibrary.wiley.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/56—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/30—Macromolecular compounds
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin, zein

Similar Documents

Publication Publication Date Title
Zivelin et al. Mechanism of the anticoagulant effect of warfarin as evaluated in rabbits by selective depression of individual procoagulant vitamin K-dependent clotting factors.
Niemetz Coagulant activity of leukocytes. Tissue factor activity
Colucci et al. Generation in plasma of a fast-acting inhibitor of plasminogen activator in response to endotoxin stimulation.
JP2766986B2 (en) Pharmaceutical compositions for preventing thrombotic occlusion or embolism of arteries
Gralnick et al. Heparin treatment for the hemorrhagic diathesis of acute promyelocytic leukemia
Innerfield et al. Intravenous trypsin: its anticoagulant, fibrinolytic and thrombolytic effects
Dubber et al. In vitro and in vivo studies with Trasylol, an anticoagulant and a fibrinolytic inhibitor
Ohlstein et al. Tissue-type plasminogen activator and streptokinase induce platelet hyperaggregability in the rabbit
Kwaan Disseminated intravascular coagulation
Than et al. Haemostatic disturbances in patients bitten by Russell's viper (Vipera russelli siamensis) in Burma
JPH0780783B2 (en) Therapeutic composition containing factor VIIa for the treatment of bleeding disorders
Matsuo et al. On the fibrinolytic and thrombolytic properties of active-site p-anisoylated streptokinase-plasminogen complex (BRL 26921)
Thompson et al. Removal of heparin and protamine from plasma
Kitaguchi et al. Effect of thrombin on plasminogen activator release from isolated perfused dog leg
Schulman Studies on the medical treatment of deep vein thrombosis
Damus et al. A purified procoagulant enzyme from the venom of the eastern diamondback rattlesnake (Crotalus adamanteus): In vivo and in vitro studies
Moore et al. Peritoneal fibrinolysis: evidence for the efficiency of the tissue-type plasminogen activator
Handley et al. A circulating anticoagulant specific for factor V
Prentice et al. Urokinase therapy: Dosage schedules and coagulant side effects
BANG Physiology and biochemistry of fibrinolysis
Sakuragawa et al. Significance of a prothrombin assay method using Echis carinatus venom for diagnostic information in disseminated intravascular coagulation syndrome
Jeljaszewicz et al. Intravascular Coagulation and Fibrinolysis by Stapliylocoagiilase. Comparison with Thrombin
Bode et al. Generation and degradation of fibrinopeptide A in stored platelet concentrate
Nalbandian et al. Consumption coagulopathy: Practical principles of diagnosis and management
Brink et al. Effects of puff-adder venom on coagulation, fibrinolysis and platelet aggregation in the baboon